ICNMD 2020, due to take place in Valencia, Spain in July 2020, has been postponed due to the COVID-19 pandemic. In its place, ICNMD is hosting a Virtual Congress, “ICNMDigital” , on 11 – 14 September 2020.
We at Biogen are delighted to take this opportunity to share important advances in the field of SMA – notably long-term outcomes of SPINRAZA® treatment in infants and children living with SMA.
During ICNMDigital, Biogen will host the second “Expert Series on SHINE” webinar, focusing on findings from the SHINE study – a long-term extension study of symptomatic patients with SMA treated in the SPINRAZA® study programme.
Featuring real patient cases and insights from the study investigators, the symposium is your unmissable chance to discover how this long-term clinical data can enhance your decision-making and transform your patient’s lives.
Time to SHINE on SMA: Exploring the evidence from SHINE, the nusinersen open-label extension study in infants and children
Francesco Muntoni, MD, FRCPH, FMedSci (London, UK) and Andrés Nascimento, MD (Barcelona, Spain)
• The nusinersen clinical development programme – Angela Paradis, ScD (Biogen)
• Setting treatment expectations in infantile-onset SMA – Francesco Muntoni MD, FRCPH, FMedSci
• Setting treatment expectations in later-onset SMA – Andrés Nascimento.
age 6 years*Later-onset (Type II) SMA
treated with SPINRAZA®